tiprankstipranks
Advertisement
Advertisement

KAPA Stock Latest News

Kairos Pharma outlines mid-year oncology pipeline and funding plans
Company AnnouncementsKairos Pharma outlines mid-year oncology pipeline and funding plans
9d ago
8K
KAPA
Kairos Pharma issues letter from CEO that recaps year, details plans for 2026
PremiumThe Fly
Kairos Pharma issues letter from CEO that recaps year, details plans for 2026
9d ago
KAPA
Kairos Pharma Highlights Clinical Programs at LD Micro
PremiumCompany Announcements
Kairos Pharma Highlights Clinical Programs at LD Micro
26d ago
8K
KAPA
Expanding Lung Cancer Franchise and Strategic Asset Acquisition Support Buy Rating on Kairos Pharma
PremiumRatings
Expanding Lung Cancer Franchise and Strategic Asset Acquisition Support Buy Rating on Kairos Pharma
3M ago
KAPA
Kairos Pharma Acquires Rights to AI-Discovered EGFR Therapy
PremiumCompany Announcements
Kairos Pharma Acquires Rights to AI-Discovered EGFR Therapy
3M ago
8K
KAPA
Kairos Pharma to acquire CL-273 from Celyn Therapeutics
PremiumThe FlyKairos Pharma to acquire CL-273 from Celyn Therapeutics
3M ago
KAPA
Kairos Pharma to acquire to two clinical-stage oncology assets from Celyn
Premium
The Fly
Kairos Pharma to acquire to two clinical-stage oncology assets from Celyn
4M ago
KAPA
Kairos Pharma Expands Lung Cancer Pipeline With Celyn Deal
Premium
Company Announcements
Kairos Pharma Expands Lung Cancer Pipeline With Celyn Deal
4M ago
8K
KAPA
Kairos Pharma files $75M mixed securities shelf
PremiumThe Fly
Kairos Pharma files $75M mixed securities shelf
5M ago
KAPA
Kairos Pharma’s Promising Clinical Developments and Strategic Focus Drive Buy Rating
PremiumRatings
Kairos Pharma’s Promising Clinical Developments and Strategic Focus Drive Buy Rating
7M ago
KAPA
Kairos Pharma Approves RSUs and Cash Bonuses
PremiumCompany Announcements
Kairos Pharma Approves RSUs and Cash Bonuses
8M ago
8K
KAPA
Promising Developments in Kairos Pharma’s Lead Candidate ENV-105 Drive Buy Rating
PremiumRatings
Promising Developments in Kairos Pharma’s Lead Candidate ENV-105 Drive Buy Rating
8M ago
KAPA
Kairos Pharma to Present at ESMO Congress 2025
PremiumCompany AnnouncementsKairos Pharma to Present at ESMO Congress 2025
8M ago
8K
KAPA
Promising Phase 2 Results and Safety Profile of ENV-105 Bolster Buy Rating for Kairos Pharma
Premium
Ratings
Promising Phase 2 Results and Safety Profile of ENV-105 Bolster Buy Rating for Kairos Pharma
9M ago
KAPA
Kairos Pharma Reports Positive Phase 2 Trial Results
Premium
Company Announcements
Kairos Pharma Reports Positive Phase 2 Trial Results
9M ago
8K
KAPA
Kairos Pharma announces interim efficacy analysis of ENV105
PremiumThe Fly
Kairos Pharma announces interim efficacy analysis of ENV105
9M ago
KAPA
Kairos Pharma’s Promising Developments and Positive Trial Data Reinforce Buy Recommendation
PremiumRatings
Kairos Pharma’s Promising Developments and Positive Trial Data Reinforce Buy Recommendation
9M ago
KAPA
Kairos Pharma to Host KOL Event on Phase 2 Trial
PremiumCompany Announcements
Kairos Pharma to Host KOL Event on Phase 2 Trial
9M ago
8K
KAPA
Kairos Pharma Presents Phase 1 Data at Conference
PremiumCompany Announcements
Kairos Pharma Presents Phase 1 Data at Conference
9M ago
8K
KAPA
Kairos Pharma: Promising Drug Pipeline and Upcoming Catalysts Drive Buy Rating
PremiumRatingsKairos Pharma: Promising Drug Pipeline and Upcoming Catalysts Drive Buy Rating
10M ago
KAPA
Optimistic Buy Rating for Kairos Pharma Driven by Promising Clinical Developments and Strong Safety Profile
Premium
Ratings
Optimistic Buy Rating for Kairos Pharma Driven by Promising Clinical Developments and Strong Safety Profile
10M ago
KAPA
Kairos Pharma management to meet with Maxim
Premium
The Fly
Kairos Pharma management to meet with Maxim
10M ago
KAPA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >